Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

p>
    Recent Highlights
    Pirfenidone:

    -- On October 16, 2008 Shionogi & Co., Ltd of Japan, which has rights to
       pirfenidone in Japan, reported approval of its j-NDA to market
       pirfenidone as Pirespa(R) in IPF.
    -- On February 3, 2009, InterMune reported results from its Phase 3
       CAPACITY program for pirfenidone in IPF, which consisted of two,
       multinational, randomized, double-blind, placebo-controlled clinical
       trials named CAPACITY 1 and CAPACITY 2.
        - The primary endpoint of change in percent predicted Forced Vital
          Capacity (FVC) at Week 72 was met with statistical significance in
          CAPACITY 2 (p=0.001), as were the secondary endpoints of categorical
          change in FVC (p=0.001) and Progression-Free Survival  (p=0.023).
        - The primary endpoint was not met in CAPACITY 1 (p=0.501), but
          supportive evidence of a pirfenidone treatment effect was observed
          on a number of measures and at various time points.  In CAPACITY 1,
          there was evidence of a pirfenidone treatment effect on the
          pre-specified secondary endpoint of Six-Minute Walk Test distance
          (p = 0.001) when compared to placebo.
        - Pirfenidone was safe and generally well tolerated in both CAPACITY
          studies.  There was no difference between pirfenidone and placebo in
          the percentage of patients that experienced a serious adverse event
          (SAE) and the pattern of adverse events (AEs) was, in general,
          comparable to that observed in previous clinical studies of
          pirfenidone.
        - InterMune is preparing an NDA for submission to the FDA, to be
          followed by an MAA submission to the European Medicines Agency
          (EMEA).
    -- InterMune reported that 603 patients from CAPACITY have been enrolled
       in RECAP, the on-going open-label roll-over study from CAPACITY to
       evaluat
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... critical, yet often overlooked factor in the medical ... effects of aggregation on both radiofrequency heating and ... oxide nanoparticles (IONPs), including detailed analysis of the ... is shown to produce significant reductions in both ... new method to quantify and correlate these effects ...
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma Inc. ... recommended approach for protecting personal data in Clinical ... patients and others. The document describes an approach ... from CSRs and other related clinical trial documents, ... The goal of the TransCelerate CSR Redaction approach ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
Breaking Biology Technology:Accounting for biological aggregation in heating and imaging of magnetic nanoparticles 2UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... Randomized Study Under Consideration, ROCKVILLE, Md., Nov. ... clinical-stage pharmaceutical company developing,therapeutics for the treatment of ... met the primary endpoint for the efficacy portion ... in combination with pemetrexed,(Alimta(R)) in non-small cell lung ...
... update on business and product pipeline, BOTHELL, ... Inc. (NASDAQ: OGXI ), a biopharmaceutical company ... that address,unmet needs in the treatment of cancer, ... and nine months ended September 30, 2008., ...
... 10 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: SCR ... generic,pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly,growing ... Morgan,Stanley 7th Annual Asia Pacific Summit 2008. The ... on November 11-13, 2008., Simcere,s chief financial ...
Cached Biology Technology:EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 2EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial 3OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2
(Date:9/2/2014)... Yale Cancer Center researchers may have discovered a ... cells made vulnerable by deficient DNA repair. , The ... Reports . , The study, led by James ... Yale School of Medicine, found that cancer cells with ... their own genetic damage) were significantly more vulnerable to ...
(Date:9/2/2014)... digital distribution of media will have lower carbon ... when file sizes are large. , That,s the ... Journal of Industrial Ecology that looked at ... as PlayStation3. Researchers found that Blu-ray Discs delivered ... than game files downloaded over broadband Internet. For ...
(Date:9/2/2014)... 2, 2014 In a new study that could ... Florida campus of The Scripps Research Institute (TSRI) have ... unique manufacturing sites for molecules that can treat a ... as a reaction vessel and a disease-causing defect as ... cell," said TSRI Professor Matthew Disney.,"Because the treatment is ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2
... pathogens rather than kill them, and although they could be ... humans. A new study to be published in the online ... drugs have the potential to fight infection while avoiding the ... kill or stop the growth of pathogens, but antivirulence drugs ...
... Diego School of Medicine say that losing the ability to ... in early hominids, and may have directed the evolutionary emergence ... findings, published in this week,s early online edition of the ... among the first evidence of a novel link between cell ...
... York and Hull York Medical School has revealed important ... by age. Working with scientists at the Peninsula ... studied responses to stress in synapses -- neuronal connections. ... such as neuro-degeneration, resulting high energy forms of damaging ...
Cached Biology News:Can antivirulence drugs stop infections without causing resistance? 2Sexual selection by sugar molecule helped determine human origins 2Sexual selection by sugar molecule helped determine human origins 3Researchers study aging's effect on the brain 2
...
solute carrier family 25, member 13 (citrin)...
... Ladder is suitable for sizing ... 16 kb by agarose gel ... be visualized by ethidium bromide ... detected on Southern blots by ...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: